Key Points
- Rebecca Taub, a Madrigal director, sold 18,650 shares on December 10 at an average of $552.15 for about $10.30 million, trimming her stake by 3.89% to 461,044 shares (valued ≈ $254.6M).
- Madrigal shares trade near $571 (52‑week range $265–$605) after a weak quarter (EPS -$5.08 vs. -$2.01 expected) and negative margins/ROE, though analysts hold a “Moderate Buy” consensus with a $562.67 average price target.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Rebecca Taub sold 18,650 shares of the business's stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $552.15, for a total transaction of $10,297,597.50. Following the transaction, the director directly owned 461,044 shares in the company, valued at $254,565,444.60. This trade represents a 3.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Madrigal Pharmaceuticals Price Performance
Shares of Madrigal Pharmaceuticals stock opened at $571.44 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.44 and a quick ratio of 3.26. The company has a market cap of $12.98 billion, a PE ratio of -43.92 and a beta of -1.04. The firm has a fifty day moving average price of $499.78 and a two-hundred day moving average price of $403.02. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $605.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 41.50% and a negative net margin of 39.04%. Analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.
Analyst Ratings Changes
Several equities analysts have commented on the company. Piper Sandler upped their price target on Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an "overweight" rating in a report on Wednesday, October 15th. Canaccord Genuity Group boosted their price objective on Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the company a "buy" rating in a research report on Thursday, November 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup reiterated an "outperform" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 5th. Finally, TD Cowen boosted their price target on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a "buy" rating in a report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $562.67.
Check Out Our Latest Research Report on MDGL
Hedge Funds Weigh In On Madrigal Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaQuest LLC grew its position in Madrigal Pharmaceuticals by 412.5% in the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 66 shares during the period. Summit Securities Group LLC bought a new position in shares of Madrigal Pharmaceuticals during the first quarter valued at $33,000. Mather Group LLC. acquired a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at $33,000. Global Retirement Partners LLC grew its holdings in shares of Madrigal Pharmaceuticals by 221.7% in the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 51 shares during the last quarter. Finally, First Horizon Corp bought a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter worth about $34,000. Institutional investors own 98.50% of the company's stock.
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
